Recent Research Analysts’ Ratings Changes for Kura Oncology (KURA)

Kura Oncology (NASDAQ: KURA) has recently received a number of price target changes and ratings updates:

• 6/15/2026 – Kura Oncology was given a new $24.00 price target by Sanford C. Bernstein.
• 6/15/2026 – Kura Oncology had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $24.00 price target on the stock.
• 6/4/2026 – Kura Oncology had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 6/4/2026 – Kura Oncology was given a new $24.00 price target by CLSA.
• 6/4/2026 – Kura Oncology was given a new $24.00 price target by Wells Fargo & Company.
• 5/28/2026 – Kura Oncology was given a new $24.00 price target by Oppenheimer Holdings, Inc..
• 5/28/2026 – Kura Oncology was given a new $24.00 price target by Jefferies Financial Group Inc..
• 5/28/2026 – Kura Oncology had its “market outperform” rating reaffirmed by Citigroup Inc..
• 5/16/2026 – Kura Oncology was upgraded by Wall Street Zen from “strong sell” to “hold”.

Insider Activity

In other news, insider Mollie Leoni sold 84,929 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total value of $834,002.78. Following the transaction, the insider owned 182,345 shares of the company’s stock, valued at approximately $1,790,627.90. This represents a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.60% of the stock is currently owned by corporate insiders.

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.